NCT Number: NCT00274729
Mono Unsaturated Fatty Acids in Obesity - Weight Maintenance and Prevention of Lifestyle Diseases in Obese Subjects.
The purpose of this study is to investigate the effect of three diets different in type and amount of fat in weight maintenance and prevention of life-style diseases in obese subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
16 year–35 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
The obesity epidemic has raised concerns, because of complications such as type 2 diabetes, cardiovascular disease and certain types of cancer. Much conflict and confusion about the optimal diet for weight control exists among the public.
The current dietary recommendations aim at reducing the total fat in the diet to less than 30% of calories, increasing carbohydrates to 55-60%, and protein from lean meat and dairy products to 15-20%, and to keep the intake of sugar sweetened soft-drinks limited. There is good evidence from meta-analyses of intervention studies that a low fat diet can prevent weight gain in normal weight individuals, induce a small but clinically relevant weight loss in overweight individuals, and also reduce the risk of cardiovascular disease and type 2 diabetes.
However this recommended diet may not be of the optimal composition in preventing the progressive increase in obesity and lifestyle diseases. The traditional dietary recommendation has been challenged by the epidemiologist Walter Willett, Harvard Medical School in Boston. He claims that dietary fat is less important for the development of obesity, and that the fat content of the diet can be 40-45% of the energy providing from mainly mono- and polyunsaturated fatty acids. Based on mainly large-scale observational studies ('Nurses Health Study') he has developed new dietary guidelines, expressed as a new diet pyramid. In contrast to the current guidelines, more plant oils and plant foods, limited animal products, such as meat and dairy products (even lean products), and increased intake of olive oil, nuts, etc., e.g. guidelines closer to the "Mediterranean Diet".
There is circumstantial evidence to support that this moderate fat, MUFA-rich diet will have a beneficial effect on some of the traditional risk factors for cardiovascular disease and type-2 diabetes. However, there is also growing concern that the increased total fat content will lead to weight gain and increased risk of obesity, and secondary to this, type-2 diabetes and cardiovascular disease. This debate has now been taken up by some of the finest scientific journals. To test this hypothesis the largest and longest dietary intervention trial in Denmark is carried out at the Department of Human Nutrition.
The objective is to identify the diet and diet components most effective for protection against weight gain, weight regain and prevention of life-style diseases in obese subjects. The three diets tested are according to:
- Willetts new dietary recommendations. High in mono unsaturated fat and low in glycemic index (50 subjects).
- The traditional dietary recommendations. Low in fat and medium in glycemic index (50 subjects).
- The average Danish diet (Control). High in fat and high in glycemic index (25 subjects).
The diets are ad libitum (i.e. no restriction in calorie intake), but very strict in dietary composition.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age: 16-35 years
- Body mass index (kg/m2): 28-36
Exclusion criteria
- Body weight fluctuations > 3 kg over the previous 2 months
- Smoking
Presence of:
- Cardiovascular diseases, cancer tumours, kidney or lever diseases, infections or endocrinological diseases, malabsorption disorders
- Systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg
- Hypercholesterolemia with changes in pharmacological treatment within the last 2 months
- Regular use of medicine other than birth pills, any psychological disorders, known or presumed abuse of alcohol, allergies to any food, special diets (eg. vegetarian) or particular dislikes
- Pregnancy, lactating or planning pregnancy within 18 month from enrolment
Treatment and study plan
Primary outcomes
-
Changes in body weight
-
Weight loss maintenance efficacy (>5% and >10%)
-
Body composition (whole body DEXA-scanning)
-
Drop-out rate
-
Glucose metabolism (Oral Glucose Tolerance Test)
-
Endothelium function (flow-mediated vasodilatation, FMD)
Secondary outcomes
-
Changes in:
-
Blood lipids
-
Blood glucose
-
HbA1c
-
Insulin
-
Blood coagulation factors
-
Waist
-
Waist/hip-ratio
-
Blood pressure
-
Appetite & diet palatability
-
Appetite regulating hormones (during meal test)
-
Visual analogue scale (VAS) (during meal test)
-
Energy expenditure (24 hour whole body indirect calorimetry)
Sponsors and collaborators
Lead sponsor
University of Copenhagen
Other
Collaborators
- Aarhus University Hospital
- Boston Children's Hospital
- Danisco
- Danish Meat Research Institute
- Harvard School of Public Health (HSPH)
- Rigshospitalet, Denmark
- Technical University of Denmark
- The Danish Dairy Research Foundation, Denmark
- University Hospital, Gentofte, Copenhagen
- Various FOOD sponsors have provided groceries for the dietary intervention
Registry information
Official study title
MUFObes: MonoUnsaturated Fatty Acids in Obesity - a Comparison Between 3 Different Diets in Weight Maintenance and the Prevention of Lifestyle Diseases in Obese Subjects. A Randomised, Long-term Intervention Study.
Important dates
- Study start
- 2004
- Study completion
- 2008
- First posted
- Jan 11, 2006
- Registry last updated
- Mar 25, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
Body Weight, Cardiovascular Diseases
Daphne, Alabama, United States
View Trial DetailsThe Impact of Stationary Combined Exercise on Adiponectin and Hs-CRP Levels in Overweight Women
NCT07230873
Body Weight, Cardiovascular Diseases
Chongqing, China
View Trial DetailsCardiovascular Risk Screening and Risk Reduction in Women Vets
NCT02991534
Body Weight, Cardiovascular Diseases
Sepulveda, California, United States
View Trial DetailsEarly Vascular Ageing in the YOUth
NCT04598685
Arterial Occlusive Diseases, Arteriosclerosis
Innsbruck, Tyrol, Austria
View Trial Details